576 related articles for article (PubMed ID: 15117890)
1. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.
Palomba S; Russo T; Orio F; Tauchmanovà L; Zupi E; Panici PL; Nappi C; Colao A; Lombardi G; Zullo F
Hum Reprod; 2002 Dec; 17(12):3213-9. PubMed ID: 12456626
[TBL] [Abstract][Full Text] [Related]
4. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
[TBL] [Abstract][Full Text] [Related]
5. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Lombardi G; Cimini V; Zullo F
Fertil Steril; 2005 Jul; 84(1):154-61. PubMed ID: 16009171
[TBL] [Abstract][Full Text] [Related]
7. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
9. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
11. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
12. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
Lethaby AE; Vollenhoven BJ
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
[TBL] [Abstract][Full Text] [Related]
13. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
Matsui S; Yasui T; Tani A; Kunimi K; Uemura H; Yamamoto S; Kuwahara A; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Clin Chim Acta; 2012 Jun; 413(11-12):960-5. PubMed ID: 22366120
[TBL] [Abstract][Full Text] [Related]
14. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
[TBL] [Abstract][Full Text] [Related]
15. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
Hansen LM; Batzer FR; Corson SL; Bello S
J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
[TBL] [Abstract][Full Text] [Related]
16. Short term treatment with leuprolide acetate is a successful adjunct to surgical therapy of leiomyomas of the uterus.
Coddington CC; Brzyski R; Hansen KA; Corley DR; McIntyre-Seltman K; Jones HW
Surg Gynecol Obstet; 1992 Jul; 175(1):57-63. PubMed ID: 1621201
[TBL] [Abstract][Full Text] [Related]
17. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
18. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
20. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
